Aligos Therapeutics (ALGS) Enterprise Value (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Enterprise Value came in at -$79.8 million in Q1 2026, up 42.16% YoY from -$56.2 million in Q1 2025, and down 333.55% on a QoQ basis from -$18.4 million in Q4 2025.
Aligos Therapeutics (ALGS) Enterprise Value (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Enterprise Value data on file, last reported at -$79.8 million in Q1 2026.
- Quarterly Enterprise Value rose 42.16% year-over-year to -$79.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$79.8 million (up 42.16% YoY) and the FY2025 annual result came in at -$18.4 million, up 67.66% from the prior year.
- Enterprise Value fell to -$79.8 million in Q1 2026, from -$18.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$18.4 million in Q4 2025 to a low of -$227.2 million in Q2 2025.
- A 5-year average of -$105.0 million and a median of -$94.6 million in 2024 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 67.66% in 2025, down 140.23% in 2025.
- Tracing ALGS's Enterprise Value over 5 years: stood at -$125.8 million in 2022, then declined by 7.93% to -$135.8 million in 2023, then surged by 58.07% to -$56.9 million in 2024, then surged by 67.66% to -$18.4 million in 2025, then slumped by 333.55% to -$79.8 million in 2026.
- The last three Enterprise Value figures came in at -$79.8 million (Q1 2026), -$18.4 million (Q4 2025), and -$99.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 2.12 Bn |
| 10 | Aligos Therapeutics | 69.36 Mn | 38.92 Mn | - | -30.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.44 Mn |
| Mar 31, 2026 | -79.83 Mn |
| Dec 31, 2025 | -18.41 Mn |
| Sep 30, 2025 | -99.21 Mn |
| Jun 30, 2025 | -227.18 Mn |
| Mar 31, 2025 | -138.01 Mn |
| Dec 31, 2024 | -56.94 Mn |
| Sep 30, 2024 | -114.49 Mn |
| Jun 30, 2024 | -94.57 Mn |
| Mar 31, 2024 | -112.92 Mn |
| Dec 31, 2023 | -135.80 Mn |
| Sep 30, 2023 | -70.50 Mn |
| Jun 30, 2023 | -90.87 Mn |
| Mar 31, 2023 | -79.07 Mn |
| Dec 31, 2022 | -125.83 Mn |
| Sep 30, 2022 | -86.52 Mn |
| Jun 30, 2022 | -71.19 Mn |
| Mar 31, 2022 | -183.22 Mn |
| Dec 31, 2021 | -187.02 Mn |
| Sep 30, 2021 | -240.39 Mn |